Capricor Therapeutics, Inc. (CAPR): Price and Financial Metrics
CAPR Price/Volume Stats
| Current price | $5.07 | 52-week high | $8.22 |
| Prev. close | $4.82 | 52-week low | $2.68 |
| Day low | $5.00 | Volume | 839,154 |
| Day high | $5.65 | Avg. volume | 296,333 |
| 50-day MA | $5.53 | Dividend yield | N/A |
| 200-day MA | $4.70 | Market Cap | 159.72M |
CAPR Stock Price Chart Interactive Chart >
Capricor Therapeutics, Inc. (CAPR) Company Bio
Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company was founded in 2005 and is based in Beverly Hills, California.
Latest CAPR News From Around the Web
Below are the latest news stories about CAPRICOR THERAPEUTICS INC that investors may wish to consider to help them evaluate CAPR as an investment opportunity.
Capricor Therapeutics (NASDAQ:CAPR) shareholders are up 16% this past week, but still in the red over the last five yearsOver the last month the Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) has been much stronger than before, rebounding by... |
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis--Favorable Interim Futility Analysis Results-- --Successful Completion Triggers First Milestone Payment Under U.S. Agreement with Nippon Shinyaku-- --HOPE-3 (Cohort A) Enrollment Complete; Topline Data Expected in the Fourth Quarter of 2024; Cohort B Enrollment Initiated-- --Company Plans to Request a Meeting with FDA in the First Quarter of 2024 to Further Discuss Opportunities for Expedited Approval Pathways-- SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), |
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call TranscriptCapricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good afternoon, ladies and gentlemen and welcome to the Capricor’s Third Quarter 2023 Financial Results and Corporate Update Call. This conference call is being recorded. I would now like to turn the conference call over to our host, Mr. AJ Bergmann, Capricor’s […] |
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update-Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy- -On Track to Report Interim Futility Analysis in Fourth Quarter of 2023; Successful Outcome Would Trigger Milestone Payment to Capricor Under Commercialization and Distribution Deal with Nippon Shinyaku- -Positive FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a Biologics License Application Submission- -Conference Call and Webcast Today |
CAPR Price Returns
| 1-mo | -23.53% |
| 3-mo | 23.66% |
| 6-mo | 86.40% |
| 1-year | 29.01% |
| 3-year | 29.34% |
| 5-year | 1.95% |
| YTD | 3.68% |
| 2023 | 26.68% |
| 2022 | 31.74% |
| 2021 | -14.58% |
| 2020 | 167.97% |
| 2019 | -68.78% |
Continue Researching CAPR
Want to do more research on Capricor Therapeutics Inc's stock and its price? Try the links below:Capricor Therapeutics Inc (CAPR) Stock Price | Nasdaq
Capricor Therapeutics Inc (CAPR) Stock Quote, History and News - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...